There is increasing demand worldwide for high-quality 
There is increasing demand worldwide for high-quality complex proteins for treating diseases and for clinical and pre-clinical studies involving recombinant proteins, vaccines, and monoclonal antibodies, many of which are the products of mammalian cell cultures. Biologics or proteinbased drugs had a global market over US$200 billion in 2016, with eight of the top 10 selling drugs with a combined global sales over US$55 billion produced using mammalian cell cultures 1, 2 . Recombinant proteins are also significant global economic drivers of both vaccine and biomarker development. In addition, it is estimated that more than half of the Australian biotechnology companies are utilising mammalian cell culture or their products 3 .
The general principles and methods to handle and genetically manipulate mammalian cells are closely related to microbial systems, for example scale-up, equipment and vector design, so a brief comparison of their attributes to traditional microbial systems is warranted.
Brief history
While mammalian cell culturing, often referred to as tissue culture, has over a 70-year history, it moved from exploratory research to a 
Genetic engineering for mammalian cultures
While general molecular and cell biology has similar tools and methods available to create and manipulate mammalian cells when compared to microbial cells, the level of complexity is much higher and thus requires greater efforts. These days the complexities of , is the most commonly used approach for the industrial scale production of complex biologics for therapeutic use.
Scale-up requirements for mammalian cultures 
Future trends
Nowadays large-scale mammalian cell cultures are well established techniques for the production of biologics in the pharmaceutical industry. During the past two decades processes were streamlined and with the wide use of Process Analytical Techniques (PAT) and
Quality By Design (QbD) 8 principles, yields and consistency of the production runs were substantially increased. This, combined with the recent introduction of single-use systems, increased both production capacity and flexibility of the pharmaceutical companies. As a consequence the cost of goods were greatly reduced, for example typical monoclonal antibody production cost should be less than US$300/g 
